CRLF2 and acute lymphoblastic leukemia: Thanks to this single-cell analysis, we uncovered distinct and clinically-relevant signaling nodes that can be successfully targeted by using a dual SRC/ABLi both in diagnostic and MRD cells, suggesting new therapeutic perspectives for patients with BCP-ALL bearing CRLF2 alterations.